Why Is No One Taking Baby Aspirin for Heart Disease Prevention Anymore?

Key Points:

• The use of baby aspirin for preventing cardiovascular disease has declined significantly, dropping from 7.2% to 3.2% among adults aged 40 and older since 2018, according to data from Epic Research analyzing 279 million primary care visits.
• Updated guidelines reflect this trend: the 2019 ACC/AHA recommendations advise against aspirin for primary prevention except in select higher-risk adults aged 40 to 70, and the 2022 USPSTF statement recommends adults 60 and older avoid starting aspirin for prevention.
• The shift is due to studies showing limited cardiovascular benefits of aspirin in primary prevention and increased risks of bleeding and gastrointestinal side effects, alongside improved management of other risk factors like cholesterol and blood pressure.
• Aspirin remains strongly recommended for secondary prevention in individuals who have experienced heart attacks, strokes, or have stents, while its use for primary prevention should be personalized based on individual cardiovascular and bleeding risk assessments.
• Patients are encouraged to consult healthcare providers for tailored advice regarding aspirin use and cardiovascular disease risk management.